1 / 13

The QA/QI Process Human Research Subjects Protection Human Investigation Committee Tracy Rightmer, JD, CIP Compliance Ma

The QA/QI Process Human Research Subjects Protection Human Investigation Committee Tracy Rightmer, JD, CIP Compliance Manager. HIC Human Research Subjects Protection Compliance Program. Goals – Strengthen and Facilitate: Safeguards for the rights and welfare of human research subjects

pallavi
Download Presentation

The QA/QI Process Human Research Subjects Protection Human Investigation Committee Tracy Rightmer, JD, CIP Compliance Ma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. The QA/QI ProcessHuman Research Subjects ProtectionHuman Investigation CommitteeTracy Rightmer, JD, CIPCompliance Manager

  2. HIC Human Research Subjects Protection Compliance Program Goals – Strengthen and Facilitate: • Safeguards for the rights and welfare of human research subjects • Responsible conduct of research involving human research subjects

  3. Current HIC Compliance Program Assurance of Compliance to the “Federal Policy” (Yale/DHHS) (Federal Wide Assurance or FWA) and to Ethical Principles (Belmont Report) Compliance after HIC approval

  4. Two Critical Program Processes • Quality Assurance • Quality Improvement

  5. Quality Assurance • Assess Compliance (regulatory, policy, approved protocol, etc.) • Resolve/correct problems and discrepancies • Verify Compliance

  6. Quality Improvement • Provide insight to where systems and processes are ineffective • Collaborative with PI and study staff • More creative and educative process • Change or add processes/procedures/guidance, etc.

  7. QA/QI Stages • Introduction/Scheduling • PI/Investigator Interviews • Staff Interview • Review of Regulatory Binder (all vital study documents -- protocol, consents, HIC correspondence, sponsor correspondence, SAE/AE reports, Investigator’s Brochure, etc.) • Review of Subject Study Records

  8. QA/QI Stages • Draft Findings Report • Release of Findings Report • Tracking of Corrective Actions/Plans, if applicable • Closure • (

  9. What Does the Reviewer Want to See? • Documentation that you are following your approved protocol • Proper use of consent forms • Following inclusion/exclusion criteria • Following study procedures • Experimental drug/device accountability • Following Data and Safety Monitoring Plan (DSMP) • Following AE collection, reporting, data review

  10. Can You Prepare Ahead of Time? • Complete the self-assessment checklist • Create a list of all participants in your study • Review each consent form & make sure it’s the correct version & has been signed/dated properly by the subject • If you find a problem with a consent, make a note in the study file and fix the problem as soon as possible (notify HIC) • Make sure you have all HIC correspondence in the Regulatory File

  11. Authorities and References • 45 CFR 46, Protection of Human Subjects • 21 CFR 50, Protection of Human Subjects • 21 CFR 56, Institutional Review Boards • 21 CFR 11, Electronic Records • 21 CFR 54, Financial Disclosure by Clinical Investigators • Applicable DHHS Office of Human Research Protection policy, guidance, and directives (including OHRP Guidebook for Human Subject Protections) • Specific grant/contractual requirements (as applicable) • FDA Information Sheets; policy statements and guidance documents • OHRP, “Dear Colleague Letters” and Determination Letters • FDA International Conference on Harmonization, Guidance on GeneralConsiderations for Clinical Trials, 62 Federal Registers 66113 (December 17, 1997) • International Conference on Harmonization, Good Clinical Practice Guidelines • Published AAHRPP Accreditation Standards

  12. Authorities and References • 21 CFR 312, Investigational New Drug Application • 21 CFR 812, Investigational Device Exemptions • The Belmont Report, Ethical Principles and Guidelines for the Protection of Human Subjects in Research, National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research-, April 1979 •  Applicable National Institutes of Health policy, guidance, and directives

  13. Authorities and References • HIC policy, procedures, and guidelines •   Yale University policy, procedures, and guidelines •   Connecticut State Statutes & Directives • Yale University Federal Wide Assurance #FWA00002571 • Specific grant/contractual requirements (as applicable)

More Related